Literature DB >> 24327696

A systems biology approach to personalizing therapeutic combinations.

Lawrence N Kwong1, Timothy P Heffernan, Lynda Chin.   

Abstract

The identification of evidence-based, efficacious drug combinations for each cancer, among thousands of potential permutations, is a daunting task. In this perspective, we propose a systematic approach to defining such combinations by molecularly benchmarking a drug against a desired state of efficacy using model systems. ©2013 AACR.

Entities:  

Mesh：

Year:  2013        PMID： 24327696      PMCID： PMC3864744          DOI： 10.1158/2159-8290.CD-13-0394

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  23 in total

1.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

2.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

3.  Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Authors:  Birgit Schoeberl; Emily A Pace; Jonathan B Fitzgerald; Brian D Harms; Lihui Xu; Lin Nie; Bryan Linggi; Ashish Kalra; Violette Paragas; Raghida Bukhalid; Viara Grantcharova; Neeraj Kohli; Kip A West; Magdalena Leszczyniecka; Michael J Feldhaus; Arthur J Kudla; Ulrik B Nielsen
Journal:  Sci Signal       Date:  2009-06-30       Impact factor: 8.192

4.  A landscape of driver mutations in melanoma.

Authors:  Eran Hodis; Ian R Watson; Gregory V Kryukov; Stefan T Arold; Marcin Imielinski; Jean-Philippe Theurillat; Elizabeth Nickerson; Daniel Auclair; Liren Li; Chelsea Place; Daniel Dicara; Alex H Ramos; Michael S Lawrence; Kristian Cibulskis; Andrey Sivachenko; Douglas Voet; Gordon Saksena; Nicolas Stransky; Robert C Onofrio; Wendy Winckler; Kristin Ardlie; Nikhil Wagle; Jennifer Wargo; Kelly Chong; Donald L Morton; Katherine Stemke-Hale; Guo Chen; Michael Noble; Matthew Meyerson; John E Ladbury; Michael A Davies; Jeffrey E Gershenwald; Stephan N Wagner; Dave S B Hoon; Dirk Schadendorf; Eric S Lander; Stacey B Gabriel; Gad Getz; Levi A Garraway; Lynda Chin
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

5.  The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.

Authors:  Tihui Fu; Qiuming He; Padmanee Sharma
Journal:  Cancer Res       Date:  2011-06-27       Impact factor: 12.701

Review 6.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

7.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.

Authors:  Mallika Singh; Anthony Lima; Rafael Molina; Patricia Hamilton; Anne C Clermont; Vidusha Devasthali; Jennifer D Thompson; Jason H Cheng; Hani Bou Reslan; Calvin C K Ho; Timothy C Cao; Chingwei V Lee; Michelle A Nannini; Germaine Fuh; Richard A D Carano; Hartmut Koeppen; Ron X Yu; William F Forrest; Gregory D Plowman; Leisa Johnson
Journal:  Nat Biotechnol       Date:  2010-05-23       Impact factor: 54.908

8.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

9.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

10.  A rapid and scalable system for studying gene function in mice using conditional RNA interference.

Authors:  Prem K Premsrirut; Lukas E Dow; Sang Yong Kim; Matthew Camiolo; Colin D Malone; Cornelius Miething; Claudio Scuoppo; Johannes Zuber; Ross A Dickins; Scott C Kogan; Kenneth R Shroyer; Raffaella Sordella; Gregory J Hannon; Scott W Lowe
Journal:  Cell       Date:  2011-04-01       Impact factor: 41.582
View more
  1 in total

Review 1.  Combine and conquer: challenges for targeted therapy combinations in early phase trials.

Authors:  Juanita S Lopez; Udai Banerji
Journal:  Nat Rev Clin Oncol       Date:  2016-07-05       Impact factor: 66.675
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.